SAN ANTONIO--(BUSINESS WIRE)--Acelity, a global wound care and regenerative medicine company, announced it has acquired the SNaP® Therapy System, a disposable negative pressure wound therapy (NPWT) line of products from Spiracur, a privately-held medical device company based in Sunnyvale, Calif. SNaP® Therapy System is designed to treat a range of complex and hard-to-heal wounds with portable, non-powered negative pressure technology, primarily in the post-acute setting. The acquisition will allow Acelity’s industry-leading sales and service channels to support the expansion of the SNaP® Therapy System to patients and their care teams around the world who need access to NPWT devices. Terms of the deal were not disclosed.
The acquisition of the SNaP® business accelerates Acelity’s plans for disposable NPWT and increases access to the post-acute market by strengthening the company’s portfolio of offerings for customers in need of comprehensive wound care solutions. This transaction amplifies the largest range of disposable negative pressure solutions while expanding patient access to these devices through Acelity’s more than 1,800 sales professionals across North America and other developed markets. The broadened Acelity portfolio has the potential to significantly alter advanced wound care outside the U.S. as portable, disposable NPWT solutions offer a more economical approach to treating chronic wounds in those geographies.
“As an organization, we continually seek out opportunities to fulfill our vision of restoring people’s lives through advancements in wound care technology,” said Joe Woody, president and chief executive officer of Acelity. “The addition of the SNaP® System complements our existing suite of clinically-proven products that speed healing and reduce costs to health systems around the world. We will continue to develop and enhance our offerings through innovation and acquisitions to remain at the forefront of healing solutions.”
SNaP® technology offers simple, off the shelf, easy-to-use products and may improve the patient experience due to its size, weight and ability to be discreet, helping mobile patients to return to their normal lives.
For more than 20 years, Acelity has been the worldwide leader in NPWT and has built the largest portfolio of advanced wound therapeutic products in the industry. Acelity has expanded its flagship V.A.C.® Therapy technology, bringing forth revolutionary solutions such as V.A.C. VeraFlo™ Therapy, the only instillation therapy on the market, which cleanses, treats and heals wounds, combining the proven benefits of NPWT with instillation therapy. In addition, Acelity’s proprietary SensaT.R.A.C.™ Technology – the only of its kind – monitors pressure at the wound site and adjusts accordingly to ensure the selected negative pressure is maintained. With the addition of SNaP® Therapy System to the company’s portfolio, Acelity has the broadest range of disposable NPWT products in the world.
“Looking ahead, we are well positioned to build upon our trusted and innovative portfolio of solutions to include near adjacencies such as easy-to-use dressings and other complementary products,” said Woody. “Working with clinicians across the continuum of care, we are expanding our focus to ensuring therapy compliance with technologies such as remote monitoring and telehealth elements that will leverage our deep knowledge and expertise.”
Acelity L.P. Inc. and its subsidiaries are a global advanced wound care and regenerative medicine company created by uniting the strengths of three companies, Kinetic Concepts, Inc., LifeCell Corporation and Systagenix Wound Management, Limited. Available in more than 75 countries, the innovative and complementary Acelity product portfolio delivers value through solutions that speed healing and lead the industry in quality, safety and customer experience. Headquartered in San Antonio, Texas, Acelity employs more than 5,700 people around the world.